Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

2019214 citationsJournal Articlehybrid Open Access

Authors

Hiddo J.L. Heerspink · University Medical Center Groningen

Bergur V. Stefánsson · AstraZeneca (Sweden)

Glenn M. Chertow · Stanford University

Ricardo Correa‐Rotter · Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Tom Greene · University of Utah

Fan Fan Hou · Nanfang Hospital

Magnus Lindberg

Abstract

DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Nephrology Dialysis Transplantation

Volume 35, Issue 2, pp. 274-282

DOI: 10.1093/ndt/gfz290

Field-Weighted Citation Impact: 24.89